BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. 1996

K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.

Phase I trials were conducted in human immunodeficiency virus type 1 (HIV-1)-infected children to examine the pharmacokinetics, safety, and antiretroviral activity of nevirapine, a nonnucleoside HIV-1 reverse transcriptase inhibitor. Nevirapine was rapidly absorbed, but the time to peak plasma concentrations increased with higher doses. Clearance was more rapid in chronic dosing studies than predicted by single-dose studies and was more rapid in younger children than in adolescent children. Rash, which occurred in 1 of the 21 study participants, was the single toxicity regarded as nevirapine-related. At doses > or = 240 mg/m2/day, 5 of 10 children experienced durable suppression of plasma p24 antigen to < 50% of baseline values through 8 weeks of nevirapine monotherapy. Viruses resistant to nevirapine were isolated from all children during therapy, but their isolation did not always predict loss of antiviral activity. The evaluation of nevirapine in combination therapy trials is underway in children.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
March 1999, Antimicrobial agents and chemotherapy,
K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
June 1994, The Journal of infectious diseases,
K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
December 2002, Antimicrobial agents and chemotherapy,
K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.
August 2005, Clinical pharmacology and therapeutics,
K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.
March 2001, Antimicrobial agents and chemotherapy,
K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
July 2001, The Journal of infectious diseases,
K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.
July 2007, European journal of clinical pharmacology,
K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.
January 2005, Antimicrobial agents and chemotherapy,
K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.
November 1995, Antimicrobial agents and chemotherapy,
K Luzuriaga, and Y Bryson, and G McSherry, and J Robinson, and B Stechenberg, and G Scott, and M Lamson, and S Cort, and J L Sullivan
Streptococcus pneumoniae in human immunodeficiency virus type 1-infected children.
August 1994, The Pediatric infectious disease journal,
Copied contents to your clipboard!